Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.21 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (t-cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: imc-gp100, epcoritamab, muromonab-cd3 +13 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 8 pathways; mostly vesicle traffic | 1.00 |
Knock down and overexpress CD3D in a dopamine neuron, astrocyte and microglia tri-culture; measure LRRK2 kinase activity (pT73-Rab10) and lysosome position and dopamine neuron survival after α-synuclein fibril challenge.
- Cell type
- a dopamine neuron, astrocyte and microglia tri-culture
- Direction
- Both arms: public data does not say which way helps; existing compounds already reach the inhibition arm.
- Molecular readout
- LRRK2 kinase activity (pT73-Rab10) and lysosome position
- Functional readout
- dopamine neuron survival after α-synuclein fibril challenge
- Rule-out
- If neither arm moves LRRK2 kinase activity (pT73-Rab10) by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of CD3D in a tri-culture of iPSC dopamine neurons, astrocytes and microglia; n = 3 differentiations; readouts: LRRK2 kinase activity (pT73-Rab10) and lysosome position; dopamine neuron survival after α-synuclein fibril challenge. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- CD3D in dopamine neurons, braak-0.32 (p 0.406) → -0.09 (p 0.815)receipt 1983
Swarm cases
receipt 1983: CD3D in dopamine neurons, braak
- power
- full sample -0.18 (p 0.487, n 18), 95% CI -0.59 to +0.32. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.14 (p 0.573, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.27 (p 0.285, n 18). could be the mix.
- skeptic
- leave-one-out range -0.30 to -0.05, sign flips 0; without severely affected donors -0.18 (p 0.487, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CD3D in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts